MIAMI, FL -- (MARKET WIRE) -- October 31, 2006 -- DOR BioPharma, Inc. (OTCBB: DORB) ("DOR," or the "Company") announced today that it has formed an alliance with the Wadsworth Center of the New York State Department of Health in Albany, New York and Lovelace Respiratory Research Institute (LRRI) in Albuquerque, NM, to build upon expertise in testing RiVax™, DOR's recombinant vaccine against ricin toxin, to protect against inhalation and oral toxin exposure. The Company has been developing RiVax™, a subunit vaccine against ricin toxin, by leading a consortium of academic and industry vaccine investigators under funding from National Allergy and Infectious Diseases (NIAID). DOR's consortium effort began in 2004 with an initial $6.4 million grant award. Recent grant funding of an additional $4.8 million has broadened the development capabilities of the program.
